UNSPSC 51162702: Ambroxol

This classification denotes a mucolytic agent and expectorant with the molecular formula C13H18Br2N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 200168S0CL, chemically known as trans-4-((2-amino-3,5-dibromobenzyl)amino)cyclohexanol but more generally known as ambroxol, which bears US NIH Compound Identifier 2132. Ambroxol most often comes in base and hydrochloride forms. European Medicines Agency schedules Ambroxol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05397MIG.

UNSPSC 51162702 Ambroxol (Commodity) covers pharmaceutical products and drug-related systems procured by state and local health agencies, though recent opportunities show the code capturing a broader range of health-related pharmaceutical acquisitions beyond the specific ambroxol formulation. State and local governments buy naloxone, over-the-counter medications, generic multi-source pharmaceuticals, and drug deactivation systems through this code. Issuing bodies include county health departments, state pharmacy programs, and multistate cooperative purchasing alliances serving multiple jurisdictions. Seminole County, Florida and the Minnesota Department of Administration's Office of State Procurement (through MMCAP) represent the repeat buyers in recent activity, with MMCAP coordinating procurement across participating state and local facilities including Oregon.

Recent opportunities span Florida and Minnesota with broader multistate reach through cooperative purchasing. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, response due July 26, 2023. The Minnesota Department of Administration issued RFP S1070000015802 through MMCAP in January 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities, with proposals due March 26, 2026 and contract effectiveness set for July 1, 2026. Both procurements emphasize compliance with federal drug-supply regulations, cGMP certification, and DSCSA requirements, with vendors required to work through authorized wholesalers and submit pricing in specific digital formats.